AR074555A1 - Combinacion de insulina con derivados de triazina y su uso para tratar diabetes - Google Patents
Combinacion de insulina con derivados de triazina y su uso para tratar diabetesInfo
- Publication number
- AR074555A1 AR074555A1 ARP090104757A ARP090104757A AR074555A1 AR 074555 A1 AR074555 A1 AR 074555A1 AR P090104757 A ARP090104757 A AR P090104757A AR P090104757 A ARP090104757 A AR P090104757A AR 074555 A1 AR074555 A1 AR 074555A1
- Authority
- AR
- Argentina
- Prior art keywords
- insulin
- denotes
- compound
- formula
- atoms
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 12
- 102000004877 Insulin Human genes 0.000 title abstract 6
- 108090001061 Insulin Proteins 0.000 title abstract 6
- 229940125396 insulin Drugs 0.000 title abstract 6
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- 150000003918 triazines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 206010063547 Diabetic macroangiopathy Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000001280 Prediabetic State Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente se refiere a una composición para ser usada como medicamento que comprende insulina en combinación con al menos un compuesto de la fórmula (1) en donde los radicales R1 a R6 tienen el significado de acuerdo con la reivindicación 1, y/o sus sales fisiológicamente aceptables, Otro objeto de la presente se ocupa de una composición farmacéutica que comprende como ingredientes activos cantidades efectivas de insulina y al menos un compuesto de la fórmula (1), junto con coadyuvantes farmacéuticamente tolerables, para el tratamiento preventivo o terapéutico y/o el monitoreo de condiciones fisiológicas y/o patológicas asociadas con resistencia a insulina. La solicitud también se refiere a un embalaje farmacéutico que comprende insulina en una primera unidad de dosificación y al menos un compuesto de la fórmula (1) en una segunda unidad de dosificación. Reivindicación 1: Una composición para usar como medicamento que comprende insulina en combinación con al menos un compuesto de la fórmula (1) y/o sus sales fisiológicamente aceptables, en donde el compuesto de la fórmula (1) se define como sigue, R1, R2 cada uno, independientemente entre sí denotan H o A, R3, R4 cada uno, independientemente entre sí, denotan H, A, alquenilo C2-6, alquinilo C2-6, Ar o Het, R5 y R6 juntos también denotan alquileno que tiene 2, 3, 4 o 5 átomos de C, R5, R6 cada uno, independientemente entre sí, denotan H, A, (CH2)nAr, (CH2)mOAr, (CH2)rnOA o (CH2)mOH, R5 y R6 juntos denotan alquileno que tiene 2, 3, 4 o 5 átomos de C, en donde un grupo CH2 puede estar reemplazado por O, NH o NA y/o en donde 1 átomo de H puede ser reemplazado por OH, Ar denota fenilo, naftilo o bifenilo, cada uno de los cuales no está sustituido o está mono-, di- o trisustituido por Hal, A, OA, OH, COOH, COOA, CN, NH2, NHA, NA2, SO2A y/o COA, Het denota un heterociclo mono-, bi- o tricíclico saturado, insaturado o aromático que tiene 1 a 4 átomos de N, O y/o S, los cuales pueden ser no sustituidos o mono-, di- o tri-sustituidos por Hal, A, OH, OA, NH2, (CH2)nAr, NHA, NA2, COOH, COOA y/u =O (oxígeno carbonilo), A denota alquilo no ramificado o ramificado C1-10, en donde 1-7 átomos de H pueden estar reemplazados por F, o alquilo cíclico C3-7; Hal denota F, CI, Br o I; m denota 1, 2, 3, 4, 5 o 6, y n denota 0, 1 o 2. Reivindicación 3: La composición de acuerdo con la reivindicación 1 o 2, en donde el compuesto de la fórmula (1) es 5,6-dihidro-4-dimetilamino-2-imino-6-metil-1, 3,5-triazina. Reivindicación 5: La composición de acuerdo con la reivindicación 4, en donde las enfermedades se seleccionan del grupo de diabetes, prediabetes, baja tolerancia a glucosa, hiperglucemia, síndrome metabólico, nefropatía diabética, neuropatía, retinopatía, arteriosclerosis y enfermedad cardiovascular, con preferencia diabetes mellitus insulinodependiente y diabetes mellitus no insulinodependiente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08021617 | 2008-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074555A1 true AR074555A1 (es) | 2011-01-26 |
Family
ID=41566311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104757A AR074555A1 (es) | 2008-12-12 | 2009-12-09 | Combinacion de insulina con derivados de triazina y su uso para tratar diabetes |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8592370B2 (es) |
| EP (1) | EP2355829B1 (es) |
| JP (1) | JP5667985B2 (es) |
| KR (1) | KR101623819B1 (es) |
| CN (1) | CN102245185A (es) |
| AR (1) | AR074555A1 (es) |
| AU (1) | AU2009326604B2 (es) |
| BR (1) | BRPI0923373B8 (es) |
| CA (1) | CA2746479C (es) |
| CY (1) | CY1115973T1 (es) |
| DK (1) | DK2355829T3 (es) |
| EA (1) | EA021395B1 (es) |
| ES (1) | ES2530223T3 (es) |
| HR (1) | HRP20150064T1 (es) |
| IL (1) | IL213421A (es) |
| MX (1) | MX2011006073A (es) |
| PL (1) | PL2355829T3 (es) |
| PT (1) | PT2355829E (es) |
| SG (1) | SG171986A1 (es) |
| SI (1) | SI2355829T1 (es) |
| SM (1) | SMT201500032B (es) |
| WO (1) | WO2010066326A1 (es) |
| ZA (1) | ZA201105094B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2579879B1 (en) * | 2010-06-09 | 2016-03-23 | Poxel | Triazine derivatives for delaying the onset of type 1 diabetes |
| TWI436768B (zh) * | 2010-06-09 | 2014-05-11 | Poxel | 第２型糖尿病之治療 |
| CA2859156C (en) * | 2011-12-12 | 2020-10-06 | Melior Pharmaceuticals I, Inc. | Treatment of type i and type ii diabetes |
| BR112020006472A2 (pt) | 2017-10-02 | 2020-10-06 | Poxel | método para tratamento ou prevenção de insuficiência cardíaca com fração de ejeção preservada (icfep) |
| CN111918655B (zh) | 2018-06-06 | 2024-05-31 | 博希尔公司 | 治疗患有慢性肾脏疾病的糖尿病受试者的方法 |
| KR20210003786A (ko) | 2018-06-14 | 2021-01-12 | 폭셀 | 당뇨병의 치료에서 사용하기 위한 트리아진 유도체를 포함하는 필름 코팅정 |
| CN114945370A (zh) * | 2019-12-13 | 2022-08-26 | 住友制药株式会社 | 具有优异可生产性和溶出性的小尺寸片剂 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3172814A (en) * | 1962-04-06 | 1965-03-09 | Jr Edgar A Ferguson | Oral blood sugar lowering compositions |
| FR2738741B1 (fr) * | 1995-09-19 | 1997-12-05 | Oreal | Composition pour la teinture des fibres keratiniques, contenant un antagoniste de substance p |
| FR2804113B1 (fr) * | 2000-01-26 | 2004-06-18 | Lipha | Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique |
| CA2436576A1 (en) * | 2001-02-02 | 2002-08-08 | Pfizer Inc. | Treatment of diabetes mellitus using vardenafil |
| DE10301788B4 (de) * | 2003-01-20 | 2005-08-25 | Aventis Pharma Deutschland Gmbh | Pharmazeutische Verwendung von Pyrimido[5,4-e][1,2,4]triazin-5,7-dionen |
| FR2896159B1 (fr) * | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline. |
| FR2896157B1 (fr) * | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. |
-
2009
- 2009-11-13 EA EA201100916A patent/EA021395B1/ru not_active IP Right Cessation
- 2009-11-13 JP JP2011539914A patent/JP5667985B2/ja active Active
- 2009-11-13 EP EP09756258.1A patent/EP2355829B1/en active Active
- 2009-11-13 KR KR1020117016022A patent/KR101623819B1/ko active Active
- 2009-11-13 MX MX2011006073A patent/MX2011006073A/es active IP Right Grant
- 2009-11-13 ES ES09756258.1T patent/ES2530223T3/es active Active
- 2009-11-13 AU AU2009326604A patent/AU2009326604B2/en not_active Ceased
- 2009-11-13 SI SI200931123T patent/SI2355829T1/sl unknown
- 2009-11-13 WO PCT/EP2009/008099 patent/WO2010066326A1/en not_active Ceased
- 2009-11-13 SG SG2011041175A patent/SG171986A1/en unknown
- 2009-11-13 PL PL09756258T patent/PL2355829T3/pl unknown
- 2009-11-13 US US13/139,027 patent/US8592370B2/en active Active
- 2009-11-13 HR HRP20150064AT patent/HRP20150064T1/hr unknown
- 2009-11-13 DK DK09756258.1T patent/DK2355829T3/en active
- 2009-11-13 BR BRPI0923373A patent/BRPI0923373B8/pt not_active IP Right Cessation
- 2009-11-13 PT PT97562581T patent/PT2355829E/pt unknown
- 2009-11-13 CN CN2009801495028A patent/CN102245185A/zh active Pending
- 2009-11-13 CA CA2746479A patent/CA2746479C/en active Active
- 2009-12-09 AR ARP090104757A patent/AR074555A1/es unknown
-
2011
- 2011-06-06 IL IL213421A patent/IL213421A/en active IP Right Grant
- 2011-07-11 ZA ZA2011/05094A patent/ZA201105094B/en unknown
-
2013
- 2013-07-15 US US13/941,677 patent/US8980828B2/en active Active
-
2015
- 2015-01-30 CY CY20151100101T patent/CY1115973T1/el unknown
- 2015-02-11 SM SM201500032T patent/SMT201500032B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074555A1 (es) | Combinacion de insulina con derivados de triazina y su uso para tratar diabetes | |
| RU2008142834A (ru) | Модуляция церамидкиназы | |
| AR055772A1 (es) | Aza -heterociclos como inhibidores de quinasas, preparacion de los compuestos y medicamento preparado en base al compuesto | |
| CO2021008055A2 (es) | Heterociclos funcionalizados como agentes antivirales | |
| EA201491335A1 (ru) | Бигуанидные композиции и способы лечения метаболических расстройств | |
| AR056986A1 (es) | Aza heterociclos como inhibidores de quinasas. procedimiento de obtencion y composiciones farmaceuticas | |
| BR112014032734A2 (pt) | derivados de pirrolidina e seu uso como moduladores da série de reação de complemento | |
| EA201300522A1 (ru) | Фармацевтические комбинации для лечения метаболических нарушений | |
| BR112015021027A8 (pt) | compostos terapêuticos, seus usos, e composições farmacêuticas | |
| AR067506A1 (es) | Derivados de quinazolinamida | |
| AR082101A1 (es) | Acidos de hidroxifenilhexinoico ariloxialquileno-sustituido, procedimiento para su preparacion y su uso como medicamento | |
| BR112013026257A2 (pt) | derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| AR081254A1 (es) | Composicion farmaceutica que comprende ave0010 e insulina glargina | |
| PE20090987A1 (es) | Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido | |
| AR080444A1 (es) | Metodos para la utilizacion de cotransportadores de sodio-glucosa 1 y 2 | |
| AR077567A1 (es) | Derivados de aminopiridina | |
| AR075582A1 (es) | Compuestos de 4- isopropilfenilglucitol | |
| MX2017004614A (es) | Preparacion compuesta, que contiene derivado novedoso de acido 3-(4-(benciloxi)fenil)hex-4-inoico y otro ingrediente activo, para prevenir o tratar enfermedades metabolicas. | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| CO6220957A2 (es) | 4-2-(4-metilfenilsulfanil-fenil piperidina con inhibicion combinada de recaptacion de serotonina y norepinefrina para el tratamiento del trastorno de deficit de atencion e hiperactividad melancolia depresion resistente al tratamiento o sintomas resid | |
| AR072860A1 (es) | Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]piridazina | |
| AR090999A1 (es) | Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos | |
| CO2018002708A2 (es) | Coterapia que comprende canagliflozina y fentermina para el tratamiento de la obesidad y de los trastornos relacionados con la obesidad | |
| PE20240933A1 (es) | Profarmaco de derivados de pirrolidona como activador de glucocinasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |